SenoRx (NASDAQ: SENO) was founded in 1998 to design, develop, manufacture and market minimally invasive devices for the diagnosis and treatment of breast cancer. Since its founding, SenoRx has developed multiple, proprietary technology platforms and a unique product portfolio that address a range of diagnostic and therapeutic procedures. These products include the EnCor® vacuum-assisted breast biopsy system, compatible with ultrasound, stereotactic and MRI modalities, the Contura™ Multi-Lumen Balloon (MLB) – the only multi-lumen applicator for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer, and the SenoSonix II-t, which combines ultrasound and vacuum assisted biopsy in one system. It is the goal of SenoRx to become the leader in the breast care market by offering products that dramatically enhance patient outcomes. SenoRx has placed thousands of its products in breast centers, hospitals, outpatient centers, and radiation oncology centers across the United States and Canada, and around the world.

SenoRx’s field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 32 countries outside the U.S. and Canada. The company’s line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is continuing development of additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information visit the company’s website at www.senorx.com